Microglia in Alzheimer's disease.
Ying Li1, Meng-Shan Tan2, Teng Jiang3
1Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China ; Department of Pathology, Qingdao Municipal Hospital, Qingdao 266071, China.
Biomed Research International
|September 9, 2014
Summary
Alzheimer's disease involves microglial activation, a key driver of brain inflammation. Targeting these immune cells offers potential therapeutic strategies for neurodegenerative disorders.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Brain Inflammation
Background:
- Alzheimer's disease (AD) is a prevalent neurodegenerative disorder in aging populations.
- AD brains exhibit significant inflammatory characteristics, with microglial activation being a central factor.
- Microglia, the brain's resident macrophages, are integral to the innate immune system.
Purpose of the Study:
- To review current perspectives on microglial activation in Alzheimer's disease.
- To examine the interplay between inflammatory regulatory systems and AD pathology.
- To explore the relationship between microglial activation and the causes and progression of AD.
Main Methods:
- Literature review of microglial activation in Alzheimer's disease.
- Analysis of inflammatory pathways and their role in AD.
- Examination of the dual functions of microglia in neuronal injury and protection.
Main Results:
- Microglial activation, triggered by beta-amyloid, is a primary driver of inflammation in AD.
- Microglia exhibit dual roles: promoting inflammation and neuronal damage, but also offering neuroprotection.
- The inflammatory response in AD is complex, involving both detrimental and potentially beneficial microglial activities.
Conclusions:
- Microglial activation is a critical component of Alzheimer's disease pathology.
- Understanding the dual roles of microglia is essential for developing effective AD therapies.
- Future strategies may focus on modulating neuronal anti-inflammatory defenses to restore immune balance in AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
16
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
16
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
13
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
13
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K